Materias dentro de su búsqueda.
Mostrando 5,821 - 5,840 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.57s Limitar resultados
  1. 5821
    por Plontke, Stefan K.
    Publicado 2021
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    100 Jahre Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie: Wo kommen wir her? Wo stehen wir? Wo gehen wir hin?
  2. 5822
    “…Resistance to Herceptin represents a significant challenge for successful treatment of HER2-positive breast cancer. Here, we show that in Herceptin-sensitive cells, FOXO3a regulates specific miRNAs to control IGF2 and IRS1 expression, retaining basic IGF2/IGF-1R/IRS1 signaling. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer
  3. 5823
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
  4. 5824
    “…PURPOSE: Equivalent efficacy was demonstrated for the biosimilar CT-P6 and trastuzumab following neoadjuvant therapy for patients with human epidermal growth factor receptor-2 (HER2)-positive early breast cancer. Following adjuvant treatment, efficacy and safety were comparable between treatments. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial
  5. 5825
    por Plontke, SK
    Publicado 2021
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    100 Jahre Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie:: Wo kommen wir her? Wo stehen wir? Wo gehen wir hin?
  6. 5826
    “…BACKGROUND: This study evaluated the trends and practice patterns associated with adjuvant chemotherapy (CT) use for patients aged ≥70 years with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–) N1 (1–3 positive lymph nodes) breast cancer (BC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of whether adjuvant chemotherapy can be safely omitted for older female patients with ER-positive, HER2-negative N1 breast cancer: a study based on the SEER database
  7. 5827
    “…BACKGROUND: The genomic tests such as the MammaPrint and Oncotype DX test are being gradually applied for hormone receptor positive/HER-2 negative (HR+/HER2-) breast cancer patients with up to three positive axillary lymph nodes (ALNs). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Candidates of Genomic Tests in HR+/HER2- Breast Cancer Patients With 1-2 Positive Sentinel Lymph Node Without Axillary Lymph Node Dissection: Analysis From Multicentric Cohorts
  8. 5828
    “…Evidence of the efficacy of pyrotinib-based treatments for HER2-positive metastatic breast cancer (MBC) in patients exposed to lapatinib is limited. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
  9. 5829
    “…Therefore, the addition of capecitabine to maintenance endocrine therapy may be a beneficial option after induction chemotherapy for HR-positive, HER2-negative AMBC patients. ABSTRACT: Optimal treatment strategies for hormone receptor (HR)-positive, HER2-negative advanced and/or metastatic breast cancer (AMBC) remain uncertain. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214
  10. 5830
    “…Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2) targeting ADC, can be a novel treatment option for HER2 alternation (mutation, expression, amplification) advanced-stage non-small-cell lung cancer (NSCLC) from DESTINY-Lung01 result. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
  11. 5831
    “…PATIENTS AND METHODS: We present a case of squamous lung cancer with high PD-L1 expression and HER2 exon 20 insertion (20Ins) who presented hyperprogressive disease (HPD) after being treated with PD-1 inhibitor. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Case Report: Tumor Microenvironment Characteristics in a Patient With HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease
  12. 5832
    por Pizzuti, Laura, Krasniqi, Eriseld, Sperduti, Isabella, Barba, Maddalena, Gamucci, Teresa, Mauri, Maria, Veltri, Enzo Maria, Meattini, Icro, Berardi, Rossana, Di Lisa, Francesca Sofia, Natoli, Clara, Pistelli, Mirco, Iezzi, Laura, Risi, Emanuela, D’Ostilio, Nicola, Tomao, Silverio, Ficorella, Corrado, Cannita, Katia, Riccardi, Ferdinando, Cassano, Alessandra, Bria, Emilio, Fabbri, Maria Agnese, Mazzotta, Marco, Barchiesi, Giacomo, Botticelli, Andrea, D’Auria, Giuliana, Ceribelli, Anna, Michelotti, Andrea, Russo, Antonio, Salimbeni, Beatrice Taurelli, Sarobba, Giuseppina, Giotta, Francesco, Paris, Ida, Saltarelli, Rosa, Marinelli, Daniele, Corsi, Domenico, Capomolla, Elisabetta Maria, Sini, Valentina, Moscetti, Luca, Mentuccia, Lucia, Tonini, Giuseppe, Raffaele, Mimma, Marchetti, Luca, Minelli, Mauro, Ruggeri, Enzo Maria, Scavina, Paola, Bacciu, Olivia, Salesi, Nello, Livi, Lorenzo, Tinari, Nicola, Grassadonia, Antonino, Fedele Scinto, Angelo, Rossi, Rosalinda, Valerio, Maria Rosaria, Landucci, Elisabetta, Stani, Simonetta, Fratini, Beatrice, Maugeri-Saccà, Marcello, De Tursi, Michele, Maione, Angela, Santini, Daniele, Orlandi, Armando, Lorusso, Vito, Cortesi, Enrico, Sanguineti, Giuseppe, Pinnarò, Paola, Cappuzzo, Federico, Landi, Lorenza, Botti, Claudio, Tomao, Federica, Cappelli, Sonia, Bon, Giulia, Pelle, Fabio, Cavicchi, Flavia, Fiorio, Elena, Foglietta, Jennifer, Scagnoli, Simone, Marchetti, Paolo, Ciliberto, Gennaro, Vici, Patrizia
    Publicado 2021
    “…To address this issue and to provide a picture of the advancement of anti-HER2 treatments, we performed a large, multicenter, retrospective study of HER2-positive BC patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
  13. 5833
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study
  14. 5834
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cost-Effectiveness Analysis from a Societal Perspective of Recurrence Index for Distant Recurrence (RecurIndex) in Women with Hormone Receptor-Positive and HER2-Negative Early-Stage Breast Cancer
  15. 5835
    “…BACKGROUND: The phase III MONALEESA-7 trial (NCT02278120) assessed ribociclib + endocrine therapy (ET) versus ET in premenopausal women with HR+/HER2− advanced breast cancer (ABC). The relationship between work productivity loss (WPL) and domains of European Organisation for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the breast cancer (BC)-specific module (QLQ-BR23) has not been explored in ABC. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer
  16. 5836
    “…BACKGROUND: For estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC), the current standard first-line treatment includes an aromatase inhibitor in combination with a cyclin-dependent kinase 4/6 inhibitor. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
  17. 5837
    “…PURPOSE: To investigate real-world clinical outcomes in patients with BRCA-mutated (BRCAm), HER2-negative metastatic breast cancer (mBC) according to BRCA and hormone receptor (HR) status. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
  18. 5838
    por Ehzari, Hosna, Safari, Meysam
    Publicado 2022
    “…The primary antibody of HER2 (Ab(1)) was immobilized on the surface of the Fe(3)O(4)@ TMU-24-AuNPs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Sandwich-Type Electrochemical Immunosensor Using Antibody-Conjugated Pt-Doped CdTe QDs as Enzyme-Free Labels for Sensitive HER2 Detection Based on a Magnetic Framework
  19. 5839
    “…Our original results open the door to further studies focused on more in-depth analysis of the molecular and clinical features related to the response to anthracycline-free neoadjuvant treatment in HER2-positive early breast cancer patients. ABSTRACT: HER2 is considered one of the most traditional prognostic and predictive biomarkers in breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status
  20. 5840
    “…Pre-clinical studies indicated its strong anti-tumor activity in HER2-positive and low HER2 expression models of BC. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report
Herramientas de búsqueda: RSS